Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Specific microRNAs and heart failure: time for the next step toward application

R. Sigutova, L. Evin, D. Stejskal, V. Ploticova, Z. Svagera

. 2022 ; 166 (4) : 359-368. [pub] 20220620

Language English Country Czech Republic

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22029535

A number of microRNAs are involved in the pathophysiological events associated with heart disease. In this review, we discuss miR-21, miR-1, miR-23a, miR-142-5p, miR-126, miR-29, miR-195, and miR-499 because they are most often mentioned as important specific indicators of myocardial hypertrophy and fibrosis leading to heart failure. The clinical use of microRNAs as biomarkers and for therapeutic interventions in cardiovascular diseases appears highly promising. However, there remain many unresolved details regarding their specific actions in distinct pathological phenomena. The introduction of microRNAs into routine practice, as part of the cardiovascular examination panel, will require additional clinically relevant and reliable data. Thus, there remains a need for additional research in this area, as well as the optimization and standardization of laboratory procedures which could significantly shorten the determination time, and make microRNA analysis simpler and more affordable. In this review, we aim to summarize the current knowledge about selected microRNAs related to heart failure, including their potential use in diagnosis, prognosis, and treatment, and options for their laboratory determination.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029535
003      
CZ-PrNML
005      
20250108155032.0
007      
ta
008      
230113s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2022.028 $2 doi
035    __
$a (PubMed)35726831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Šigutová, Radka $u Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava and Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 jo2015853716
245    10
$a Specific microRNAs and heart failure: time for the next step toward application / $c R. Sigutova, L. Evin, D. Stejskal, V. Ploticova, Z. Svagera
520    9_
$a A number of microRNAs are involved in the pathophysiological events associated with heart disease. In this review, we discuss miR-21, miR-1, miR-23a, miR-142-5p, miR-126, miR-29, miR-195, and miR-499 because they are most often mentioned as important specific indicators of myocardial hypertrophy and fibrosis leading to heart failure. The clinical use of microRNAs as biomarkers and for therapeutic interventions in cardiovascular diseases appears highly promising. However, there remain many unresolved details regarding their specific actions in distinct pathological phenomena. The introduction of microRNAs into routine practice, as part of the cardiovascular examination panel, will require additional clinically relevant and reliable data. Thus, there remains a need for additional research in this area, as well as the optimization and standardization of laboratory procedures which could significantly shorten the determination time, and make microRNA analysis simpler and more affordable. In this review, we aim to summarize the current knowledge about selected microRNAs related to heart failure, including their potential use in diagnosis, prognosis, and treatment, and options for their laboratory determination.
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $7 D035683
650    12
$a srdeční selhání $x diagnóza $x genetika $x terapie $7 D006333
650    _2
$a biologické markery $7 D015415
650    _2
$a fibróza $7 D005355
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Evin, Lukáš $u Department of Internal Medicine and Cardiology, Department of Cardiovascular, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0327372
700    1_
$a Stejskal, David, $u Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava and Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $d 1967- $7 xx0042302
700    1_
$a Ploticova, Vera $u Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava and Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Švagera, Zdeněk, $u Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava and Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $d 1975- $7 osd2015860757
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $x 1804-7521 $g Roč. 166, č. 4 (2022), s. 359-368
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35726831 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20250108155027 $b ABA008
999    __
$a ok $b bmc $g 1885631 $s 1180860
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 166 $c 4 $d 359-368 $e 20220620 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK138 $a Pubmed-20230113

Find record

Citation metrics

Archiving options